Table 3.
Studies of immune checkpoint inhibitors in ovarian cancer with reported results
| Immunotherapy agent(s) | Trial number | Disease status | Phase | N | Results (N; duration) | G3/4 adverse events | Reference |
|---|---|---|---|---|---|---|---|
| Ipilimumab | recurrent EOC, previously treated with GVAX vaccine | I | 9 | PR (1; 35+ mos.) SD (3; 1 for 6+ mos.) | diarrhea | Hodi et al. [50] | |
| BMS-936559 (anti-PD-L1) | NCT00729664 | recurrent EOC | I | 17 | 6% PR (1; 1.3+ mos.) 18% SD (3; 6+ mos.) | infusion-related reaction, adrenal insufficiency | Brahmer et al. [80] |
| Nivolumab | platinum resistant EOC | II | 20 | 10% CR (2; 11+ mos.) 5% PR (1; 11+ mos.) 30% SD (6; 1 for 11+ mos.) | lymphocytopenia, hypoalbuminemia, elevated ALT, rash, fever, anemia | Hamanishi et al. [25] | |
| Pembrolizumab | NCT02054806 | recurrent EOC, PD-L1 positive | Ib | 26 | 4% CR (1; 6+ mos.) 8% PR (2; 6+ mos.) 23% SD (8; 2 for 6+ mos.) | transaminitis | Varga et al. [26] |
| Ipilimumab | NCT01611558 | recurrent EOC | II | 40 | 10% BRR (4; NA) | NA | clinicaltrials.gov [27] |
| Avelumab | NCT01772004 | recurrent EOC | Ib | 124 | 10% PR (12; 4 for 6+ mos.) 44% SD (55; NA) | rash, edema, elevated amylase/lipase, arthritis, colitis, hyperglycemia/DM | Disis et al. [28] |
| Durvalumab + Olaparib | NCT02484404a | recurrent EOC | I/II | 10 | PR (1; 11+ mos.) SD (7; 4+ mos.) | Lymphopenia, anemia | Lee et al. [29] |
| Durvalumab + Cediranib | 4 | PR (1; 7 mos.) SD (2; 1 for 6 mos.) | Lymphopenia, anemia, nausea, diarrhea, hypertension, PE, pulmonary hypertension, fatigue, headache |
Abbreviations: N number of ovarian cancer patients treated, EOC epithelial ovarian cancer, CR complete response, PR partial response, SD stable disease, ALT alanine aminotransferase, BRR best response rate (CR/PR status not provided), mos. months, NA not available, DM diabetes mellitus; PE, pulmonary embolism
aAs of data cut-off date: May 10, 2016